All In Biotech

Drug Trial Radar · NCT06253130

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

156

Planned (sponsor's estimate)

Start

Dec 11, 2023

Primary completion

Jun 1, 2027

Study completion Dec 1, 2027

Sponsor

Lead sponsor
Eikon TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Impact Therapeutics, Inc.
First posted
Feb 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 89 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • IMP1734Drug

    PARP1 selective inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with adverse events, treatment emergent adverse events or serious adverse eventsTime frame: Consent to 30 + 7 days post last dose of IMP1734
  2. Maxim Tolerated Dose or Recommended Dose for ExpansionTime frame: DLT period is from the first dose of the study drug until the last day of the first cycle

Locations

57 sites in 8 countries. Site status is shown where the registry gives one.

  • The University of Arizona Cancer Center

    Tucson, Arizona · Recruiting

  • University of Arkansas Winthrop P. Rockefeller Cancer Institute

    Little Rock, Arkansas · Recruiting

  • Hoag Health Center Irvine

    Irvine, California · Withdrawn

  • University California Irvine

    Irvine, California · Withdrawn

  • Sharp Memorial Hospital

    San Diego, California · Withdrawn

  • University of California San Francisco (UCSF)

    San Francisco, California · Withdrawn

  • Sarah Cannon Research Institute Health One

    Denver, Colorado · Recruiting

  • Smilow Cancer Hospital at Yale New Haven

    New Haven, Connecticut · Recruiting

  • Advent Health Research Institute

    Celebration, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Henry Ford Health

    Detroit, Michigan · Recruiting

  • University of Minnesota-Clinical Research Unit

    Minneapolis, Minnesota · Recruiting

  • Washington University - Siteman Cancer Center

    St Louis, Missouri · Withdrawn

  • John Theurer Cancer Center

    Hackensack, New Jersey · Withdrawn

  • Cayuga Medical Center

    Ithaca, New York · Withdrawn

  • Lifespan Cancer Institute

    Providence, Rhode Island · Recruiting

  • Medical University of South Carolina (MUSC) - Hollings CC

    Charleston, South Carolina · Recruiting

  • West Cancer Center & Research Institute

    Germantown, Tennessee · Recruiting

  • Sarah Cannon Research Institue Oncology

    Nashville, Tennessee · Recruiting

  • START - South Texas Accelerated Research Therapeutics

    San Antonio, Texas · Withdrawn

  • START Mountain Region

    West Valley City, Utah · Withdrawn

  • Scientia Clinical Research Ltd

    Randwick, New South Wales, Australia · Active not recruiting

  • Mater Cancer Care Centre, Mater Misericordiae Limited

    South Brisbane, Queensland, Australia · Recruiting

  • Gold Coast Private Hospital

    Southport, Queensland, Australia · Not yet recruiting

  • Macquarie University

    Sydney, Queensland, Australia · Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia · Recruiting

  • Peninsula and south eastern haematology and oncology group

    Frankston, Victoria, Australia · Recruiting

  • Cross Cancer Institute

    Edmonton, Alberta, Canada · Recruiting

  • Sunnybrook Research Institute

    Toronto, Ontario, Canada · Recruiting

  • Princess Margaret Cancer Centre-University Health Network

    Toronto, Ontario, Canada · Recruiting

  • Chongqing University Cancer Hospital

    Chongqing, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Recruiting

  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.